Lp,s are doomed!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/C/Cannabis/Gesetzentwurf_Cannabis_Kabinett.pdf
Doomed from the get go…lol
Home / Cultivation
German cabinet sends diluted recreational cannabis bill to Parliament
By MJ wattsStaff
August 16, 2023
Europe’s largest economy inched closer to ending marijuana prohibition after the German federal cabinet gave the green light to a watered-down bill to legalize some recreational cannabis use.
The cabinet’s approval this week is an important step from Germany’s three-party governing coalition and marks a milestone for the cannabis industry in Europe.
The draft law now heads to the Bundestag – Germany’s Parliament – which is expected to make changes to the law.
“The Cannabis Act marks a turning point in what has unfortunately been a failed cannabis drug policy. The aim is to push back the (illicit) market and drug-related crime, curb the dealing in adulterated or toxic substances and reduce consumer numbers,” Health Minister Karl Lauterbach said in a news release.
The bill lays the legal footing for “nonprofit cultivation associations” – clubs of up to 500 people – which will be strictly regulated.
The measure also:
Allows adults to grow up to three cannabis plants for their own consumption as well as for community, noncommercial cultivation for their own consumption in grow associations or cooperatives.
Bans advertising and sponsorship for consumer cannabis and cultivation associations.
Limits the transfer of consumer cannabis via growers’ associations to members only,
with a limit of 25 grams per day or 50 grams per month.
Limits distribution to people 18-21 years old to no more than 30 grams per month.
Their THC limit will be 10%.
Limits distribution to dried marijuana and hashish.
The draft law mandates an evaluation take place on the social impact after four years.
Germany had originally intended to fully legalize cannabis but decided on a lighter, two-track approach after running into resistance from the European Commission – the European Union’s executive branch.
The German Hemp Association hailed the draft as a “milestone” on the way to reforming cannabis policy.
The body said the move could put an end to criminalizing relatively minor consumption-related offences.
However, the association is hopeful major issues will be addressed in the parliamentary process.
Some include:
An “unrealistic” ban on consumption in cannabis cultivation clubs.
Hefty penalties and fines for small violations of “already arbitrary limits.” For instance, the group said possession of 25 grams will be made perfectly legal, but 26 grams would carry a prison sentence of up to three years.
Germany is expected to bring forward a second law, the timing of which is not yet confirmed, to facilitate regional pilot projects with commercial supply chains.
I cannot answer private message questions. I have a free account. No consulting either. Freedom baby!
Folks purchase legacy weed for 5 reasons.
They sell bulk.
They sell cheap.
They have the good stuff.
They ship quickly.
Their weed is fresh, not stale like old lp’s bunk.
Before the stock is worth buying, the company needs to show some consistent lowering of its costs, and experiencing faster growth wouldn't hurt either. Unfortunately, it's likely going to be stymied on both those fronts by it’s poor quality products and the sorry state of the Canadian cannabis market, which is flooded with cheap marijuana that's putting a crimp on margins. Likewise, the stock market heavily disfavors marijuana companies and unprofitable companies at the moment, and Tilray falls into both of those buckets.
Lps are your today bootleggers . Lol
Legacy rules and lps are going down in flame.
Simon is lobbying hard for the cops to come in. Lol
To no avail…
So they keep on growing mold.
Until they pop.
A little google research on Tilray’s reputation would do you good.
History is all ready repeating itself… lol
How many more billions lost after all those years growing legal bunk.
Tell me when Tilray will start making money selling legal weed?
How many years before they crash?
And look where they are today. A huge global footprint with plenty of first mover positions in place. Plenty of cash on hand to cover operations and still growing. This industry is still in its infancy and they are making the right moves to be a leader early in the game.
Amazing 9 years operating and constantly lost money. How long would they have been able to do that running as a private company ?
Wait, are there people out there who believe Tilray is profitable?
— David George-Cosh (@itsdgc) August 15, 2023
Mexican cartel only deal in crystal meth, guns, sex slave and Fentanyl.
Chinese dark web fentanyl is 300$ per once delivered next day to Mexico.
I would not deal with your friends but…
The Canadian cannabis Legacy market is killing it right now on the web.
Check these 1000 of canna growers on You Tube…
Your lp?
Not so much.
Breeding mold is a bitch. Lol
headz.cc for all your daily deals.
Nowhere to go but down…
Mexican cartel only deal in crystal meth, guns, sex slave and fentanyl.
They essentially kill folks.
Just walk down Kensington on You Tube or Hasting in Vancouver or any us city.
Sad. Really sad. It could have been your daughter.
Chinese dark web 300$ per once delivered next day to Mexico.
I would not deal with your friends but…
The Canadian cannabis Legacy market is killing it right now.
Your lp?
Not so much.
Breeding mold is a bitch. Lol
headz.ca
The police is doing the leg work for Health Canada.
A reminder of pre-legalisation hells angels breaking bones.
Cannabis is medicinal.
I wish the cops stop bothering folks for weed.
Waist of money.
No need for Mexican cartel in Canada.
It doesn't’ make the grade anyway.
[color=red][color=red]LEGACY RULES, HAS TRACTION![/color]
[/color]
They BRAKE this market.
But you would not be aware of it…
Living under a rock, sound 😴 … lol
New MAGA hit : Jail House Rock by the King
Hard worker who know better
Rico will kick your ass… lol 😂
Yes, we aware of it…
You will be a billionaire… lol
HEALTH CANADA ORDERED TO REVIEW ORGANIGRAM CASE
Avatar photoCALEB MCMILLAN·AUGUST 15, 2023
ALL ABOUT CANNABIS
CANNABIS 101
CANNABIS CANADA
CANNABIS LEGALIZATION
CANNABIS NEWS
FEATURED
HEALTH
LATEST LEGALIZATION NEWS
LAW
MARIJUANA LEGALIZATION
MARIJUANA NEWS
POLITICS
POLITICS
THC NEWS
A federal judge has ordered Health Canada to review its Organigram case over what constitutes a cannabis edible.
Earlier this year, Health Canada sent cease and desist letters to LPs. They accused the licensed producers of selling cannabis edibles masquerading as extracts.
Organigram was one of these LPs. Health Canada said their lozenges, known as Jolts, were really edibles. This decision put the product under a different regulatory umbrella, namely, a cap of 10mg of THC per unit.
So Organigram contacted their lawyers. Justice Cecily Strickland ruled that Health Canada was wrong. The federal health bureaucracy will have to review its initial decision and reassess.
Of course, Health Canada can determine that its initial decision to classify lozenges as edibles was correct. And then we’re back at square one.
But right now, it’s Organigram 1, Health Canada 0.
PARTIAL VICTORY FOR ORGANIGRAM
Health Canada Organigram
It’s music to our ears to hear a federal court order Health Canada around. But, as mentioned, Health Canada could make the same decision regarding the Organigram case.
The federal court also didn’t address Organigram’s main complaint: Health Canada made this decision after approving the lozenges as extracts. Jolts have been on the market since August 2021. It wasn’t until early 2023 that Health Canada decided to flex their bureaucratic muscles.
Justice Strickland did not rule on the “reasonableness” of Health Canada’s compliance letter. She said there was a “breach of procedural fairness” with its initial decision. Ergo, return to the drawing board and see if you screwed up.
Only in government can people investigate themselves for any potential wrongdoing.
Organigram wanted the court to annul Health Canada’s extract-edible decision. So, this is only a partial victory.
Justice Strickland ruled that Health Canada didn’t give Organigram ample time (or even an opportunity) to respond to their claims. The federal bureaucracy objected to the lozenges’ size and shape. They claimed it was too big to put under the tongue.
In her ruling, Strickland said: “I found no evidence in the record before me to support its inference that the size and shape of the Jolts may cause consumers to not follow the instructions for use.”
WHY THIS HEALTH CANADA-ORGANIGRAM CASE IS IMPORTANT
Health Canada Organigram
This Health Canada—Organigram case is important for several reasons. An already struggling cannabis industry shouldn’t have to wage these battles over the petty attitudes of Canada’s regulatory bureaucrats.
A cannabis product labelled an “extract” can have 100 times more THC than an edible.
Bureaucrats shouldn’t be handing out cease and desist letters at the 11th hour. That’s not how healthy Western democracies work. That’s how banana republics work.
Nobody wants to invest in a country where bureaucrats interpret “public health and safety” as interfering with consensual capitalist acts between adults.
Organigram wasn’t harming their customers by selling Jolts. And customers weren’t being duped or harmed by voluntarily buying the product.
Health Canada is chasing a boogeyman. Or perhaps, this entire ordeal was plain old bureaucratic inefficiency.
In her decision, Justice Strickland wrote:
[T]he process by which Health Canada assesses the classification of products, as submitted by producers, as either edible cannabis or cannabis extract, is relatively new and appears to have been in transition during the time leading up to the making of the decision… in an effort to avoid future challenges based on procedural fairness, Health Canada should consider clearly identifying the policy(s) and procedures upon which it will rely in making determinations of non-compliance based on the classification of cannabis products and inform concerned parties concerned accordingly.
In other words, don’t be a black box of information. Communicate with the companies you’re apparently regulating. Of course, we prefer voluntarily-funded accreditation agencies.
FOOTNOTE(S)
https://stratcann.com/wp-content/uploads/2023/08/Organigram-Inc-and-Minister-of-Health-and-AG-of-Canada.pdf
Having a CEO who is canna naive is where you fail big time…
Poor Simon don’t know what to do next as more weed is being destroyed.
More problems ahead tells me you should purchase more shares as prices are going down weekly.
https://cannabisnow.com/women-of-influence-wanda-james/
Wanda James IN THE MAGAZINE The Pioneer
Photos courtesy of Wanda James
Breaking boundaries is second nature to dispensary owner Wanda James.
ByJoy KingPublished on August 15, 2023
As one of the most profoundly accomplished female entrepreneurs in cannabis, Wanda James is simultaneously shattering the glass and grass ceilings. The founder and CEO of the Denver-based dispensary, Simply Pure, is blazing a trail for not only women of color, but for women in general.
James is the first legally licensed African American dispensary owner in the US. She attributes that to her strong work ethic; a willingness to trust her intuition; a readiness to pivot when necessary; and the influence of her “remarkable” father, who raised James and her brother alone.
“My dad used to always tell me, ‘If you’re ever walking down the street and something tells you to turn left, but you need to keep going straight, follow your gut: Turn left,’” James says. “He always told me not to let someone talk you out of not feeling that instinct.”
James learned to trust her gut and listen to her intuition—an ability that helped her form a strong sense of self and build a successful career as an adult. She says she never felt that growing up without a mother changed who she was or who she could become. Being part of a family without traditional gender roles helped form her expectations of the future: As she saw it, anything was possible.
After graduating from the Naval ROTC program as the first Black female in 1986, James admits she didn’t understand the significance of many of her accomplishments until years later. She found discipline and structure within the military, something James admits she needed at the time. So, James didn’t realize that it was uncommon for her to be the only Black woman in ROTC, or the only female officer or one of very few Black executives in corporate America. She says she didn’t realize she was America’s first Black dispensary owner either.
“I didn’t even know that until I think it was MSNBC that brought it up, because I didn’t know it was unusual,” she says. “The more I’m experiencing and looking back, I’m now saying, ‘Well, dang, I was the only woman. I was like, ‘Go me!’”
Her work as a Fortune 500 Executive, a small business owner and a leading advocate in the cannabis industry led James to work with government leaders including President Obama, Vice President Harris, Sen. Kirsten Gillibrand, Rep. Barbara Lee and Colorado Governor Jared Polis. She says she focuses on social equity, justice and ending the War on Drugs. She ran for election to the University of Colorado Board of Regents representing District 1 and won in Colorado’s general election on November 8, 2022. With yet another achievement, James is a first-generation graduate of CU Boulder. Combined with the fact that there hasn’t been a Black woman on the Board of Regents since the 1980s, it’s another remarkable accolade in her career.
James admits that some of her life’s most significant decisions weren’t planned.
“When the universe presents something to you in a moment—whatever that is—your ‘spidey’ senses, your gut, all of a sudden, it all comes together and it’s like, that’s what you’re doing,” she says. “And so, I wish I could tell you—even with everything with cannabis, even with going to college and joining the military—all of those decisions were things that the universe presented me with at a time when that wasn’t what I was looking for. But it all said, ‘Say yes.’”
Wanda James with Vice President Kamala Harris
But the road hasn’t always been easy. James says it’s these tougher experiences—learning how to overcome hardships—that have provided her with many of the skills necessary to succeed. James made this clear while speaking to a political science class at CU Boulder. A student asked about her many career highlights, so she started running through her triumphs, but then, she suddenly stopped and said, “I need you to all understand that all of this happened because other things didn’t go right.”
Even in the competitive landscape that Denver dispensaries operate, she says her shop’s superpower is that they’ve remained small and have yet to take on any debt. Also, James says their ultimate success is because of the people behind the work.
“We’re like The Little Engine That Could,” she starts. “Nobody has been greedy. My investors have held on even when they don’t always get dividends. But we’ve all looked at it as if we’re almost at the point of legalization. It’s been the people who work there as well as what we believe about the plant. And it shows. We take time to explain things to customers; we’re not trying to rush them in and out. We’re doing the antithesis of what every consultant says you should be doing in a retail operation.”
When it comes to counseling women trying to break into the industry, James isn’t all sunshine and roses—not even close.
“Whenever I’m asked about advice I’d give to women about entering the cannabis industry, I’m always torn between wanting to give the uplifting answer that I know somebody in my position should deliver to folks,” she says. “It should be something like, ‘Hey, believe in your dreams, and yes, your cake can be on the shelf of every dispensary out there.’ But, sadly, that’s not the case at all. I’ve always been about entrepreneurism. I love being an entrepreneur. I’m wired that way. Not everybody is wired to be an entrepreneur.”
James emphasizes the importance of understanding what you’re getting yourself into. While some people may have their heart set on starting and growing a business, others may be better suited working alongside a team of passionate employees.
“There are incredible careers and high-paying jobs in the cannabis space,” she says. “If you’ve never run a business, if you don’t understand mass distribution, if you’re not looking at scaling your product line the same way Coca-Cola scales, then in that case, you’re in the wrong business. If you’re not looking to build that kind of business, sitting in front of a computer most days, having countless meetings with people you may not like very much and who don’t understand your passion and don’t speak your language, cannabis may not be your calling.”
Luckily for James, cannabis was the siren call she never knew she needed to answer. After a lifetime of groundbreaking firsts—in cannabis and in business—this dynamic force of nature is determined to keep following her gut and continue making her father proud.
Legalized bunk weed has no traction!
Canna prices dropping weekly… or when will you pop?
Home / Finance
Poseidon cannabis ETF to shut down less than 2 years after launching
author Kate Robertson
August 15, 2023
The AdvisorShares Poseidon Dynamic Cannabis Exchange Traded Fund (ETF), which is managed by the Paxhia sibling founders of California-based cannabis hedge fund Poseidon Investment Management, is shutting down less than two years after launching.
The move reflects the multiple headwinds facing the industry – such as falling wholesale prices and the slow pace of federal reform – as well as dwindling investor interest in marijuana stocks.
The ETF’s final day of trading will be Aug. 25, according to a notice on the fund’s website.
A statement of additional information published to the site said the actively managed fund will liquidate its assets and distribute the proceeds to shareholders on Sept. 1.
The price of the ETF has decreased by nearly 90% since it launched in November 2021 on the New York Stock Exchange (NYSE) Arca under the ticker symbol PSDN, declining from $9.33 to approximately $1 in recent months.
That’s an even steeper drop than the Pure US Cannabis ETF (MSOS), another actively managed ETF under the Maryland-based investment firm AdvisorShares umbrella, which declined by about 84% over the same period.
Morgan Paxhia, co-founder and managing director of Poseidon Investment Management, said the fund is another casualty of dwindling investor interest in the cannabis industry.
Siblings Morgan and Emily Paxhia founded Poseidon Investment Management in San Francisco in 2013.
“The PSDN fund is not immune to the broader macroeconomic environment and, more specifically, the dramatic shift in investor sentiment that has impacted the cannabis industry,” he said.
If Legacy was under Health Canada, they would go down in 🔥.
LP’s are doomed.
Health Canada don’t like weed.
Home / Cultivation
Canadian court hands Organigram partial win in ‘edible’ cannabis dispute
author profile pictureBy Matt Lamers, International Editor
August 15, 2023
SHARE
What’s the right revenue per square foot? What’s a realistic business outlook for cultivators? Get realistic market forecasts, state-by-state insights and benchmarks. Get the 2023 Factbook.
Image of a package of Organigram's Edison Jolts lozenges
Packages of Organigram Holdings' Edison Jolts cannabis lozenges. (Photo by Matt Lamers)
Health Canada breached its duty of procedural fairness when it decided that licensed producer Organigram Holdings’ lozenges should be classified as “edible” cannabis rather than extracts, a federal justice said in granting the company’s application for judicial review.
Justice Cecily Strickland kicked the decision back to Canada’s health department to review its initial decision and make a new determination involving the lozenges, known as Jolts.
ADVERTISEMENT
Millions of dollars could be at stake in the outcome of the legal dispute, given that cannabis extracts are potentially a much more lucrative product than edibles under Health Canada’s classification system for ingestibles.
In an interview with MJBizDaily, Organigram CEO Beena Goldenberg said the decision is a “win” for the company, even though Health Canada might ultimately return the same decision.
“Our decision to seek a judicial review was unprecedented in the cannabis industry,” she said.
Still, the federal court did not address Organigram’s key assertion: Health Canada had treated the company unfairly by deciding Organigram needed to yank the lozenges from store shelves years after they were introduced into the market.
The justice also did not rule on the “reasonableness” of Health Canada’s initial decision.
Moncton, New Brunswick-based Organigram had asked the court to quash the Health Canada decision, saying the ruling effectively killed off the market for the products, which had become an increasingly popular segment of the struggling cannabis sector.
Historic decision
Still, Strickland’s decision is historic when it comes to the cannabis industry.
It was the first time a licensed producer applied for a judicial review of a decision made by Canada’s federal government.
Organigram originally launched Jolts in August 2021. Health Canada’s crackdown on extracts wasn’t evident until early 2023.
The distinction between a cannabis edible and extract has major implications for the marketability of those products in Canada.
That’s because any cannabis product classified as an “extract” has 100 times more allowable THC per package than a product classified as an “edible,” making it more appealing to some consumers.
Health Canada did not immediately respond to queries from MJBizDaily, so it’s unclear how long the regulator will take in making its redetermination.
“Essentially what she (the justice) is saying to Health Canada is they have to reissue the compliance letter, and you have to give Organigram the opportunity to respond to it, including the issues raised at the 11th hour,” Trina Fraser, a partner at Brazeau Seller Law in Ottawa, Ontario, who leads the firm’s cannabis practice, told MJBizDaily in a phone interview.
“And then you have to make the decision over again.
“Organigram went to the federal court with a plea that the minister’s decision was unreasonable. But. unfortunately, we didn’t get a decision on that issue.”
ADVERTISEMENT
The ruling
Strickland said the Canadian government failed to give Organigram an adequate opportunity to respond to one of the key factors on which Health Canada relied when making its decision.
“When all of the circumstances of the case are taken into account, I find that there was a breach of procedural fairness arising from inadequate notice of Health Canada’s reliance on a factor contained in the Compliance Promotion Statement and, as a result, that Organigram was not afforded a meaningful opportunity to respond to that concern and thereby prejudiced in its ability to respond to that concern,” the justice noted in her decision.
According to Strickland, Health Canada made the key decision based in part on an internal document called the Classification Policy, which was not referenced in the federal agency’s decision involving the lozenges.
The Classification Policy focuses on the classification of ingestible cannabis products and is dated Sept. 8, 2022.
“The specific concerns raised in the notice of noncompliance are said to have been based on the classification factors of product representation, product format, and public perception or history of use,” Strickland wrote.
“These are the three factors set out in the Classification Policy, which appears to be an internal Health Canada document.”
However, the Classification Policy is not referenced in the notice of noncompliance provided to Organigram and other licensed producers.
Strickland also said the lack of notice and disclosure of Health Canada’s concerns arising from a fourth factor – the physical characteristics of the Jolts – “precluded Organigram from responding to concerns not previously raised in the notice of noncompliance.”
The justice added that Health Canada introduced the fourth factor in its decision – the product’s sensory and physical characteristics – but that was omitted from the notice of noncompliance sent to the company.
In effect, Strickland ruled that Organigram was not given an opportunity to respond to Health Canada’s objection to Jolts’ size and shape or suitability for sublingual use, which was one of the key reasons Health Canada rejected the lozenges being classified as an extract.
In her ruling, the justice “found no evidence in the record before me to support (Health Canada’s) inference that the size and shape of the Jolts may cause consumers to not follow the instructions for use.”
Organigram’s Goldenberg, for example, told MJBizDaily the instructions on the Jolts package “say to put it under your tongue or between your gum and cheek for sublingual absorption.”
Strickland also flagged Health Canada’s procedures.
“The process by which Health Canada assesses the classification of products, as submitted by producers, as either edible cannabis or cannabis extract, is relatively new and appears to have been in transition during the time leading up to the making of the decision,” she said.
“Health Canada should consider clearly identifying the policy(s) and procedures upon which it will rely in making determinations of noncompliance based on the classification of cannabis products and inform concerned parties concerned accordingly,” she suggested.
‘Action plan,’ if necessary
For her part, Goldenberg called the decision a “win.”
“I think the verdict was a win for Organigram in that Health Canada was found to have procedural unfairness, they had brought other factors into their determination of Jolts as an ‘edible’ than what was in the original guidance to licensed producers in terms of product classification,” she said.
Goldenberg said the company plans to provide the agency with some relevant facts.
“For example,” she said, “one of the points Justice Strickland made was that Health Canada added a factor (in its final decision) of the physical size and shapes of the Jolts.”
Goldenberg contends Health Canada’s point of view was that, given the size and shape, the product doesn’t fit well under the tongue.
“But our product was designed specifically for that use (to fit under a tongue or between a gum and cheek),” she said.
“We have some new information to share with Health Canada. Maybe they might not consider it; maybe they will come to the same determination.
“But they have to go back and revisit it, and they have to provide us a chance to provide that information.”
What happens if Health Canada still renders the same decision?
“We’re assessing various options with respect to what we want to do with the future of Jolts, based on whatever Health Canada’s reconsideration is,” Goldenberg said.
“At this point, we don’t want to go down that path until the door is (fully) shut on what was a successful product.
“Depending on how quickly this reassessment happens, we will have an action plan in place.”
The justice’s decision is available here.
— what should I do with the water (@EamonCyr) August 15, 2023
Quebec has limited plans for new cannabis stores under retail monopoly
Solomon Israel
August 14, 2023
Nearly five years after recreational cannabis legalization, legal weed shops are as common as corner stores in most major Canadian cities.
In the biggest metropolis, Toronto, more than 400 cannabis retail licenses have been issued across the city’s six boroughs.
In contrast, Canada’s second-biggest city – Montreal – is home to only 21 legal cannabis outlets within city limits, plus some stores in outlying suburbs.
All are operated by Quebec’s government-owned recreational cannabis retail monopoly Société québécoise du cannabis (SQDC).
Despite having only 98 stores across all of Quebec, the SQDC monopoly appears to have limited plans to open new outlets over the next several years.
Because Canada’s maturing cannabis market has shown a clear link between growing store numbers and increasing legal marijuana sales, Quebec’s restricted retail expansion plans raise questions about how much further the regulated industry can grow sales in Canada’s second-most-populated province.
SQDC’s latest annual report revealed that sales plateaued at 601.9 million Canadian dollars ($449 million) in the retailer’s latest fiscal year ended March 25, barely increasing over the previous year at a time when overall sales of legal cannabis in Canada were growing.
Other factors – such as labor unrest, a lack of legal vape sales and restrictions on sales of cannabis edibles – also play into Quebec’s flatlining sales.
No matter the cause, it’s clear that Quebec punches well below its weight in terms of legal cannabis sales compared to other Canadian jurisdictions. Legault and his bureaucrats are against canna legalization.
In May, Quebec sales of legal recreational marijuana totaled CA$52.5 million for an estimated total population of 8.8 million, outpaced by the smaller provinces of Alberta (CA$74.3 million in sales; 4.7 million people) and British Columbia ($64.8 million in sales; 5.4 million people).
Low store numbers, ongoing labor dispute
Michel Timperio, executive chair of the board of provincial marijuana industry group Association Québécoise de l’Industrie du Cannabis (AQIC), believes the province should have more retailers than the existing 98 and assumes new stores would benefit producers, as sales would presumably increase.
“It’s hard for me to say what would be the ideal number of stores,” Timperio said.
“I believe, though, that if we had more stores, it would be better for accessibility by consumers.”
Bonno's duh moment.
For now, though, Timperio believes the SQDC has a bigger issue than the number of stores: An ongoing strike by workers at 24 SQDC locations has dragged on for well over a year, resulting in rotating store closures and reduced hours as the stores are staffed by managers.
“That is more of a concern right now than opening more stores,” Timperio said.
SQDC spokesperson Fabrice Giguère noted in a statement that both parties have agreed on “non-monetary issues,” but salaries and the length of the collective agreement are still under negotiation.
“Currently, there is no scheduled date for a negotiation meeting,” Giguère wrote, adding that the SQDC “aims to find a solution to welcome our colleagues back to work.”
A labor dispute with SQDC workers represented by a different union was resolved in 2022.
Meanwhile, the SQDC’s latest strategic plan for 2024 through 2026 makes no mention of plans to open new stores, although it does say the retailer will “continue diversifying our delivery and pick-up services and look into ways of extending our presence across Quebec.”
The retailer told us that it doesn’t have a target for the number of new stores it will open by 2026.
Spokesperson Giguère subsequently added that the SQDC would consider opening new stores in a “few market gaps” over the next three years.
Aside from that possibility, according to Giguère’s statement, the retailer “strongly believe(s) that consumers can have proper access to legal cannabis products with our store network covering the territory of Quebec and the different delivery services, including our 90-minute service.”
In light of recent research showing the link between consumer proximity to legal cannabis stores and the increased odds of those consumers making a purchase from the legal market, Quebec’s relatively small number of brick-and-mortar stores suggests that some would-be legal consumers aren’t being captured by the legal market.
“We don’t know what’s behind their strategy in terms of where they’re going to be going after these 98 (stores),” said the AQIC’s Timperio, who raised the possibility that the SQDC might eventually open different kinds of stores, such as express outlets, in smaller markets.
Canadian cannabis market researcher Michael Armstrong, an associate business professor at Brock University in St. Catharines, Ontario, believes Quebec is “the one province that needs more stores, even for basic public policy objectives.”
“But not necessarily drastically more stores,” Armstrong qualified.
Government retail monopolies such as Quebec’s can have fewer stores than a private-sector market “and still have equivalent coverage (and) convenience,” he observed.
The SQDC’s retail monopoly is highly profitable, reporting net income of CA$94.9 million ($70.3 million) for its fiscal year ended in late March.
Challenges for legal cannabis sales in Quebec
SQDC spokesperson Giguère wrote that the SQDC’s plateauing sales are “in part due to the ongoing labor dispute,” adding that “this stage is completely normal within the growth curve of any new business operating within a new industry.”
Although cannabis market researcher Armstrong believes the strike plays into the SQDC’s sales leveling off, he said, “I’m sure that the plateauing of the store numbers is a big contributor to the plateauing of sales.”
Other factors also account for Quebec’s low cannabis sales relative to other provinces, particularly a political focus on cannabis-related health concerns.
Quebec law prohibits sales of many popular forms of edible cannabis, including candies, chocolates or anything that could be “attractive to persons under 21 years of age.”
Edibles currently for sale at the SQDC include unconventional options such as cannabis-infused beef jerky, baked beets or apricot and reishi mushroom bites.
Also, cannabis concentrates sold by the SQDC may not contain more than 30% THC, leaving room for hashish sales but ruling out sales of more potent extracts such as shatter or wax.
What’s more, the SQDC has chosen not to sell cannabis vape pens and cartridges – a popular product category in the rest of Canada – with spokesperson Giguère citing a 2018 recommendation from Quebec’s public health institute that expressed concern about the safety of vapes.
Giguère said the SQDC is “fully aware and concerned by both the scale and importance of the problem caused by vaping habits among young people” and “will be happy to be part of the solution when the (health institute) decides to change its stance on the matter in the future.”
Home cultivation of recreational cannabis is banned in Quebec, precluding sales of starting materials like cannabis seeds or clones. Done matter, folks cop from web.
Finally, Quebec’s government has forbidden the sale of recreational cannabis to consumers younger than 21, a higher minimum age than in any other province.
Quebec ‘a distinct society’
The AQIC’s Timperio said the SQDC has “done a good job” within the limitations set by Quebec’s government.
“They’re a bit handcuffed in what they can do,” he said. It’s legalization after all… lol
The SQDC’s ability to take additional cannabis market share away from illicit sellers is limited in light of the fact that the retailer doesn’t sell certain products, Timperio said. Limited? SQDC lose market share daily.
That’s “unfortunate,” he added, “because the main objective of creating legalization was to try to eradicate the black market.”
Timperio said the SQDC deserves credit for paying producers for orders quickly and for having a “well-structured and organized” logistics operation.
“They deliver their mandate very well to the government,” he said.
“But, unfortunately for them, they have a very limited mandate.”
Business professor Armstrong also praised aspects of the SQDC’s business model.
“There’s some things they should do differently, which is more stores,” he said.
“There’s some things they’re doing well, which is pricing, operational efficiency.
“And there’s some things they have no control over, like the minimum legal age. … And they can’t sell any of the edibles that people actually want to buy.”
Armstrong observed that Quebec is, “in many ways, a distinct society” within Canada.
Quebec is historically “more accepting of alcohol, but they also historically are less accepting of cannabis,” he said.
The AQIC’s Timperio said Quebec’s provincial government wasn’t enthusiastic about participating in Canada’s federal cannabis legalization effort and “would have liked, probably, to take more time.”
Timperio added: “Quebec has always been more of a progressive province, which is not the case with cannabis.”
Business
Judiciary – Judges’ association sharply criticizes draft cannabis legalization law
August 12, 2023
The German Association of Judges (DRB) has criticized the Federal Ministry of Health’s draft cannabis law. There were warnings of additional burdens on the judiciary.
The German Association of Judges (DRB) has criticized the Federal Ministry of Health‘s draft cannabis law. “In particular, the judiciary will not be relieved by the legislative plans, but rather an additional burden,” said Sven Rebehn, Managing Director of the Judges’ Association, in the Saturday editions of the editorial network Germany. Critical tones also came from some federal states and municipalities.
“The very small-scale law would lead to a high level of official control, numerous new disputes and many procedures before the courts,” criticized Rebehn. Some of the planned penal provisions are associated with considerable difficulties in providing evidence and a large investigative effort for the public prosecutor’s office.
“Administrative court proceedings or neighborly disputes relating to cannabis cultivation are likely to increase,” predicted Rebehn. In addition, it is hardly to be expected that the black market will be pushed back as a result.
The draft law provides that the purchase and possession of up to 25 grams of cannabis should remain unpunished in the future – even if bought on the black market. Up to three plants should be allowed in self-cultivation at home. “But because there are a number of hurdles to growing yourself or purchasing from growers’ associations, demand on the black market is likely to grow in the wake of the cannabis law,” Rebehn warned.
According to Health Minister Karl Lauterbach (SPD), the federal cabinet is expected to discuss the limited release of cannabis planned by the government next Wednesday. Parallel to the legislative process, there should be “a major campaign” “to point out the risks of cannabis consumption,” said Lauterbach.
See also Plantix: AI that detects diseases in plants is sold
NRW Minister of Health Karl-Josef Laumann (CDU) again criticized the legalization and planned model projects for the controlled sale of cannabis. “I fundamentally reject the legalization of cannabis and thus also model projects,” said Laumann of the “Rheinische Post”. Among other things, he referred to the “risk of cannabis-related brain damage in adolescents and young adults”.
The managing director of the NRW City Council, Helmut Dedy, called for more money for addiction help before the federal cabinet discussed legalization of cannabis. “In the future, the federal and state governments will have to co-finance the municipal drug and addiction help in the cities. This includes, for example, prevention offers, but also educational offers for consumers,” Dedy told the “Rheinische Post”. This applies in particular to the protection of young people. However, the prevention work should not only concern cannabis, but also other addictive substances such as nicotine or alcohol.
Most cannabis operators have invested their fortunes into businesses that won't be able to prosper until federal policy reforms are achieved yet, contrary to legacy market, they invest nothing in the work needed to achieve those reforms.
Wow… i did not know that… Tilray must be rich by now?
Get it go?
Bedrocan's founder says: "What I have always been doing is producing on demand. That is a core rule in the company. Figure out the demand, then live up to that level and, if needed, expand."
Those 3 sentences alone would have prevented over $20 billion in losses at Canadian LPs. Lol…
But but but there is no demand for bunk stock market weed.
Agree, they don’t know how to work that canna caper.
Who are you going to call?
Get a CEO who has at the very least did the Pepsi challenge.
I don,t like lps in general…
Not suited for the job at 🤚.
Great at losing money selling mold for a high dollar.
This doctor don,t like sick folks being gauged by lps.
BC Bud was killing it but they wanted to reinvent the wheel.
They did not want to sell good cannabis.
They wanted to sell shares…
So you have cannabis market naive suckers pilling shares.
Lps are pilling mold.
They are fucked big time.
Who are you going to call whey they drop the ball?
Veterans shafted!
Toronto earns ‘Big Smoke’ title as Canada’s biggest cannabis toker
August 11, 2023 by David Wylie
Toronto residents consume the weight of nearly three elephants worth of weed.
Three Canadian cities are on top of the world when it comes to how much cannabis they consume.
The 2023 Cannabis Global Price Index used data from 140 cities worldwide—both legal and not—then ranked them in a number of categories.
“Cannabis consumption figures were collected from WHO (World Health Organization) for countries around the world,” says the CFAH, which is behind the study.
Toronto (No. 7), Montreal (No. 13), and Vancouver (No. 16) broke the top 20 cities in terms of annual pot use. Those in the Big Smoke consumed 16.7 metric tons—roughly the weight of three male African elephants. Montrealers came in at 11 metric tons, and Vancouverites at 7.9.
The top city was New York at 62.3 metric tons—about the weight of a Boeing 737—followed by Sydney, Australia; Los Angeles; Chicago; and Rome, Italy.
“We examined the top and bottom cannabis-consuming nations to choose the study cities,” say the authors.
Among the surprising information, Brandon, Man., out-smoked Calgary. The small Prairie community in the heart of Mennonite country managed to consume 5.9 metric tons of weed, compared to the much more populous Calgary’s total of 2.8.
When it comes to price, Tokyo, Japan, has the highest price per gram at $33.80, more than $10 a gram more expensive than runner-up Dublin, Ireland, at $22.50.
CFAH found legalizing cannabis leads to a drop in the price of cannabis.
“Legalizing cannabis is more likely to cause a price decline in the market, with prices falling by 11.13% on average,” it says.
They also found countries with strong cannabis consumption rates are 30% more likely to have low gram prices.
The 15 cities with the highest cannabis price per gram:
The chart shows 15 cities with the highest price per gram, as well as whether it's a legal or illegal market.
Legacy wins everywhere.
DOOMED!!!
Canopy repeats going concern doubts amid falling cannabis sales.
Borisek may be on to something…
Bonno
August 10, 2023
Canopy Growth Corp. reiterated doubts about its ability to stay afloat when the Canadian cannabis producer reported its fiscal 2024 first-quarter results.
In a filing with the U.S. Securities and Exchange Commission, Canopy said it has 259.6 million Canadian dollars ($193 million) in required principal repayments to be settled in cash within the next 12 months.
“If we are unable to raise additional capital, it is possible that we will be unable to meet certain of our financial obligations,” Canopy disclosed in the filing.
“These matters, when considered in the aggregate, raise substantial doubt about our ability to continue as a going concern.”
Canopy first issued the going concern warning in June.
In a note to investors, Toronto-based BMO Capital Markets analyst Tamy Chen wrote that “the risk with the stock is that our model still requires the company to raise CA$200 million (in fiscal 2025) to continue operations.
Failure to do so would result in a cease of its going concern status.”
In the quarter ended June 30, Canopy narrowed its loss to CA$42 million, an improvement compared with the company’s CA$2.1 billion loss in the first quarter last year.
However, Canadian cannabis sales fell to the ground.
Recreational marijuana revenue declined 9% to CA$24.2 million in the first quarter compared to last year.
Canopy said adult-use sales fell primarily because of lower sales volumes across its premium and value-priced product categories, which for the latter was largely the result of a strategy shift away from low-margin products.
Canadian medical cannabis sales improved 7% to CA$14.4 million in the April-June quarter.
International medical cannabis sales fell 25% to CA$10.2 million.
Despite BioSteel’s strong sales, analyst Chen noted that the unit continued to be a drag on the company’s overall losses, accounting for approximately 60% of the company’s negative adjusted earnings before interest, taxes, depreciation and amortization (EBITDA).
In May, Canopy disclosed plans to refile some of its financial statements for the fiscal year ended March 31, 2022 after identifying “material misstatements” related to BioSteel sales.
BioSteel continues to be the subject of an investigation by the SEC.
The Ontario Securities Commission (OSC), the regulatory agency that administers and enforces securities rules, is conducting an “informal inquiry.”
“While the Company is fully cooperating with the SEC and the OSC with respect to these inquiries, it cannot predict when such matters will be completed, the further timing of any other developments in connection with these matters, or the outcome and potential impact,” Canopy said in the filing.
“If the SEC or OSC initiates a civil enforcement proceeding against the Company for alleged violations of securities laws or regulations, (Canopy Growth) may face a variety of civil sanctions and penalties, including … financial penalties and awards, injunctive relief and compliance conditions, which may have a material adverse effect on the financial condition or results of operations.”
Class action lawsuits have been filed, Canopy also noted, alleging violations of securities laws after the company announced the plans to refile some financial statements.
“Substantial damages or other monetary remedies assessed against the Company could have a material adverse effect on our business, financial condition, results of operations and cash flows,” Canopy warned.
Canopy had cash and cash equivalents worth CA$53.3 million and debt of CA$1.05 billion as of June 30.
All is well…
Simon is buying!
He buying time really… dude wants to keep his job…
Until he gets tossed out after spending what is left.
Lps are doomed!!!
Marijuana industry spends millions lobbying as shutdown threatens SAFE Banking
Chris Roberts
August 10, 2023
The cannabis industry continues to spend millions of dollars on high-powered lobbyists to sway U.S. senators to pass marijuana reform, but those efforts could be thwarted this fall by a government shutdown that threatens to upend Congress’ legislative calendar.
U.S. marijuana companies and trade groups spent more than $2.4 million lobbying the U.S. Senate in the first half of 2023, according to the most recent federal lobbying disclosure filings.
That’s less than the $2.9 million spent on trying to woo the Senate over the second half of 2022, including the lame-duck session when cannabis banking reform seemed tantalizingly close.
Still, this year's dollars have been funneled to influential lobbying firms stocked with Capitol Hill veterans, including a former Democratic Senate majority leader and a former top aide to President Joe Biden.
While some companies have curbed spending or canceled contracts entirely given the economic and financial headwinds battering the industry, other firms have come to grips with the reality that a lobbying outlay is the cost of survival.
Yet, so far, the results have been frustratingly familiar: Popular, long-sought-after reform measures including guaranteed access to banking and more ambitious goals such as rescheduling still remain just out of reach, if frustratingly close.
As lawmakers head home to their districts for the August recess, the SAFE Banking Act’s chances of passage in President Biden’s first term remain alive - for now.
But the odds of passage will steadily dwindle without the passage of vital spending bills, according to congressional aides and Capitol Hill lobbyists.
“As we get later in September, if that’s not getting done, this could be a real problem," said one cannabis industry lobbyist who requested anonymity in order to speak freely.
"A government shutdown would suck all the air out of the room."
Shutdown looming
Congress’ main concern after reconvening on Sept. 5 will be to pass necessary spending bills to avoid a government shutdown on Oct. 1.
Triggered when Congress can't pass spending bills, a shutdown is a major disruption that, as of now, looks likely, as the Brookings Institution, a Washington DC-based think tank, recently observed.
The longer Congress goes without a spending deal in place, the less time there will be on legislative calendars for other business.
That includes the SAFE Banking Act receiving its long-promised Senate Banking committee markup hearing, the prerequisite before a vote on the full Senate floor.
That’s the “regular order” process that advocates promised would happen this year.
SAFE Banking did make history this spring by getting a mid-May informational hearing.
A markup hearing, in which amendments are introduced and debated and the bill potentially altered in a public forum, was promised this summer, first in June and then in July.
But bipartisan squabbling over the bill’s final form - as well as a desire to secure more Republican co-sponsors to ensure SAFE Banking has the necessary 60 votes to bypass cloture - led to the Senate adjourning for August recess without that hearing.
Additional requests from companies that already have bank accounts are further complicating the picture.
Lobbyists for publicly traded cannabis companies have proposed adding language to SAFE Banking that would allow access to major U.S.-based exchanges, such as the Nasdaq.
Most cannabis multistate operators currently trade on the smaller Canadian Securities Exchange.
However, most Washington observers agree the major sticking points for such a proposal remain anti-money-laundering language as well as whether SAFE Banking can secure enough Republican co-sponsors to guarantee passage on the full Senate floor.
And lobbying records confirm the obvious: Though federal rescheduling and, eventually, a nationwide legal industry like Canada's remain on the wish list, SAFE Banking is the marijuana industry's top priority.
The marijuana “industry appears to be exclusively focused on SAFE to the exclusion of everything else, and, therefore, the members are responding accordingly,” said Don Murphy, a veteran Washington DC lobbyist and director of government relations for the Texas-based Marijuana Leadership Campaign.
Until SAFE passes, “nothing else,” such as rescheduling, “will have any juice,” he added.
"After all, if Congress can’t pass even the smallest of incremental reforms like banking, what hope is there for comprehensive reforms?"
Meanwhile, the Biden administration's review of marijuana's status under the Controlled Substances Act continues in the background, though it's generally accepted on Capitol Hill that necessary reform will have to come from Congress.
And with SAFE Banking having repeated success in the House of Representatives but being stymied in the Senate, most attention has shifted to the Senate.
Top dollars
Marijuana industry spending reflects these priorities, as well as the issue's urgency and the need to curry favor with well-connected Washington power players.
New York-based Curaleaf Holdings was the marijuana industry’s top spender on Capitol Hill with a reported $450,000 worth of lobbying activity, according to the most recent quarterly Lobbying Disclosure Act forms filed in late July.
The company paid for its in-house lobbyist, Matt Harrell, and also retained Denver-based Brownstein Hyatt Farber Schreck, one of the nation’s largest lobbying firms, according to records.
Ohio-based Scott’s Miracle-Gro reported spending $400,000 in 2023, with $180,000 of that spent on DC-based BGR Group’s government affairs team and another $100,000 on Brownstein.
Cresco Labs spent $250,000, hiring both Brownstein as well as DC-headquartered Putala Strategies, whose principal, Chris Putala, is a former Senate aide to President Biden.
Cannabis companies were also represented by dedicated DC-based advocacy groups, including:
The Coalition for Cannabis Policy Education and Regulation, or CPEAR, whose funders include tobacco giant Altria Client Services. CPEAR spent $340,000.
The National Cannabis Roundtable, which reported spending $330,500.
The U.S. Cannabis Council, which spent $210,000.
Advocates and critics both point out that the marijuana industry’s spending on crafting friendly federal policy, while far and above past years, still pales in comparison to the cash splashed by entrenched special interests such as defense contractors and pharmaceutical companies.
“Markets are bad. There’s price compression. All the capital’s dried up. But we tell our counterparts: We know business is bad, but it’s either give up or get to DC,” John Sullivan, the chief lobbyist for Chicago-based Cresco Labs, told Chris in a phone interview.
“This is the only way to fix it."
Dead after Christmas?
If Congress can quickly come to terms on a spending bill in September, that likely would allot plenty of time for a SAFE Banking markup hearing and vote in the Senate, said Reggie Babin, a former top aide to Sen. Chuck Schumer and now senior counsel at DC-based Akin Gump Strauss Hauer & Feld, another well-connected law firm retained by marijuana companies to represent their interests.
“I’ve always pointed to October as the most likely window to carve out a couple of weeks” for SAFE Banking, Babin told MJBizDaily in an interview.
“But that could be complicated if there’s a shutdown that costs you legislative days in the fall.”
If October passes without that hearing, there’s a definite time crunch.
Though some prominent voices such as Curaleaf chair Boris Jordan have said that early 2024 is a good time to pass SAFE Banking, several cannabis lobbyists speaking on background agreed the bill's chances are greatly reduced if there’s no vote before the end of this year.
Curaleaf did not provide comment by the deadline for this story.
There’s also some feeling on Capitol Hill that marijuana reform is a mostly Democratic Party issue, meaning Republicans might be loath to contribute to what could be seen as a Democratic win in a presidential election year, one lobbyist said.
Also this fall, the industry should see the reintroduction of some more ambitious marijuana legislation such as the States Reform Act championed in past sessions by Rep. Nancy Mace, a South Carolina Republican.
That bill, which legalizes marijuana at the federal level but delegates many regulatory powers to individual states, could reappear in Congress as soon as next month, a Mace spokesperson said.
However, most of the attention and resources will continue to be spent on SAFE Banking, though the looming government shutdown is the main obstacle that’s out of the marijuana industry’s control.
And the longer SAFE Banking lingers in committee, the less likely any other reform remains.
Simon is buying!
He buying time really… dude wants to keep his job…
Until he gets tossed out after spending what is left.
Lps are doomed!!!
Germany’s scaled-back cannabis law still faces EU hurdles
Germany’s cannabis ambitions could still be partially incompatible with European Union law, even though Berlin significantly scaled back the initiative.
In particular, Germany’s plan for cannabis clubs would be “complicated” in terms of EU law because members would be consuming recreational cannabis they did not grow themselves
Canada’s federal government accounts for a growing share of the unpaid debts racked up by failed cannabis companies, lending credence to claims the nation’s nascent adult-use industry is suffering from pricey fees, heavy taxation and low quality products.
A review of recent insolvency filings by MJBizDaily found that the Canada Revenue Agency, the federal tax collection body, and Health Canada, the national department in charge of regulating cannabis production, are commonly among the biggest unpaid creditors for insolvent marijuana producers.
Cannabis CULTURE
Fully Half Of American Adults Have Tried Marijuana, With Current Cannabis Smoking Outpacing Cigarettes, Gallup Poll ShowsPublished 5 hours ago on August 10, 2023 By Kyle Jaeger
Fully half of Americans have tried marijuana, according to a new Gallup poll—and more people now actively smoke cannabis than tobacco cigarettes. Additionally, a majority say they are not especially concerned about the effects of adults regularly using marijuana
The survey, published on Thursday, found that about one in six U.S. adults (17 percent) say that they currently smoke cannabis, while separate recent Gallup polling shows that just 11 percent say they smoke cigarettes.
Further, the marijuana question—which asked specifically about whether people “smoke” the substance—likely does not reflect overall current cannabis use given the range of non-smokable products that people consume such as edibles, tinctures and vapes. But when it comes to smoking, it’s become clear that Americans are increasingly opting for marijuana over cigarettes.
Looking at generational data, the trend appears likely to continue. Broken down by age, 29 percent of those 18-34 say they currently smoke marijuana. In contrast, a Gallup survey from last year showed that 12 percent of people 18-29 smoke cigarettes. (The age groupings used in the polls are slightly different but comparable).
Meanwhile, with nearly half of the states in the country now having legalized marijuana, the new poll shows lifetime use has hit a record high of 50 percent, up just two percentage points from 2022 but statistically higher than 2019, when 45 percent said that they’ve tried cannabis.
Via Gallup.
When Gallup first polled people about whether they’ve experimented with marijuana in 1969, just four percent of respondents said that they had. That “increased sharply in the first decade after the initial measure,” rising 20 percentage points by 1977, Gallup’s Justin McCarthy noted in the new analysis published on Thursday.
“It rose another nine points, to 33 percent, by 1985, but thereafter stalled at under 40 percent until 2015, when it ticked up to 44 percent,” he said. “It remained at about that level through 2019 but then rose to 49 percent in 2021, roughly where it is today.”
The finding that 17 percent of Americans say they currently smoke marijuana is also not a major increase compared to the 16 percent who said the same last year. But again, it’s markedly higher than when Gallup first asked the question in 2003, when just seven percent said they smoke cannabis.
Again, however, the language of the question is somewhat exclusionary. Most current marijuana consumers do say that they primarily smoke it, but a 2019 study published by the American Medical Association found other consumers report primarily using edibles (nine percent), vapes (nine percent) and concentrates (three percent) and drinks (0.4 percent).
For the most part, there aren’t significant differences in the demographics of adults who say they’ve tried cannabis, the new poll shows.
Lifetime consumption is consistent across age groups: 18-34 (49 percent), 35-54 (51 percent) and 55+ (47 percent). College graduates and non-graduates are both at 49 percent. Men are slightly more likely to have experimented with cannabis (54 percent) compared to women (44 percent).
Via Gallup.
The largest divide identified by Gallup was party affiliation, with Democrats the most likely to have tried marijuana (57 percent), followed by independents (52 percent) and Republicans (39 percent). Democrats are also nearly twice as likely (21 percent) to report active cannabis smoking compared to Republicans (12 percent).
Another recent analysis from the firm also discussed the partisan gap in support for cannabis legalization. A majority of Republicans and Democrats, as well as those who lean toward one party or the other, both support ending prohibition, but Democrats have more quickly embraced the issue over the past two decades.
The latest survey additionally asked respondents to rate their level of concern about the effects of cannabis use on adults and teens. For adults, a majority (55 percent) said that they were either “not at all concerned” or “not too concerned,” versus 45 percent who said they were either “very concerned” or “somewhat concerned.”
That changes when people are asked about the effects of marijuana on young adults and teens, with 75 percent saying that they’re either very or somewhat concerned about it.
Via Gallup.
“As marijuana has become more available to Americans and legal in an increasing number of states, their reports of use and experimentation have increased too. Now, half of the country has tried it, while the other half say they never have,” Gallup concluded. “Experimentation with marijuana among most subgroups is on par with the national average, but the rate of current use varies more—and is highest among young adults.”
The new poll is based on telephone interviews conducted between July 3-27 with a random sample of 1,015 adults, and has a margin of error of ±4 percentage points.
Public support for marijuana legalization, meanwhile, has also continued to grow amid the state reform movement.
A series of three polls that were released earlier this year showed that most Americans are ready to end federal marijuana prohibition, regardless of party affiliation.
Legacy still holds 85% of all Canadian cannabis sales.
Your wife knows that you cannot afford it… lol
She would’nt mind otherwise…lol…
Have you read the proposition?
I tell you right now that they are doomed right from the start!
It,s actually much worst than Canada’s so call “legalization”.
My first post here in 2014 called the weed stock market growing at scale b.s.
Sure got a lot of flacks from naive canna stock market folks.
It was designed to fail by Health Canada and it did fail big time.
They had the perfect model in BC Bud.
2023 BC Bud is killing it while lps grow mold.
Lol…
While everyone else is playing by the ridiculous regulations re: advertising & getting crushed by taxes, Billionaire
@RyanGosling out here on YouTube @YTAdvertisers promoting an unlicensed undated mushroom / weed service …. You can’t make this sh!t up
Nice work Health Canada!
Doomed is the word. Canadians knows better! Lol again…
From 214.06$ in 2018…
Not bad…lol